Cell Cycle, Cell Death and Cellular Adaptation

Cell Cycle Regulation

The cell cycle is the ordered sequence by which a cell duplicates its genome and divides into two genetically identical daughter cells. Its regulation is central to normal growth, tissue repair, embryogenesis, hematopoiesis, and carcinogenesis. The core principle is that progression through the cycle requires activation of specific cyclin-dependent kinases (CDKs) by phase-specific cyclins. Cyclin concentrations rise and fall cyclically, whereas CDK protein levels are relatively constant.

Phases of the Cell Cycle

Phase	Key Event	High-Yield Features
G0	Quiescence	Nondividing state; cells may be reversible, stable, or permanent. Neurons and cardiac myocytes are classically permanent.
G1	Cell growth and preparation for DNA synthesis	Most variable phase; major restriction point regulated by Rb, E2F, cyclin D/CDK4/6, and p53.
S	DNA synthesis	Genome content doubles from 2N to 4N DNA, while chromosome number remains 46 until mitosis.
G2	Preparation for mitosis	Checks completion and integrity of DNA replication before mitosis.
M	Mitosis and cytokinesis	Includes prophase, metaphase, anaphase, telophase; chromosome segregation depends on spindle attachment.

The total cell cycle length varies by tissue. Rapidly proliferating cells, such as intestinal crypt epithelium and bone marrow precursors, divide frequently; mature neurons and skeletal muscle fibers generally remain in G₀. In flow cytometry, G₀/G₁ cells have 2N DNA content, S-phase cells have intermediate DNA content, and G₂/M cells have 4N DNA content.

Cyclins, CDKs, and Checkpoints

CDKs are serine/threonine kinases that phosphorylate target proteins to drive cycle progression. They require cyclin binding for activation and are inhibited by CDK inhibitors. The major cyclin-CDK pairs are highly testable.

Transition	Main Cyclin-CDK Complex	Function
Early G1	Cyclin D-CDK4/6	Phosphorylates Rb, promoting progression through the restriction point.
Late G1 to S	Cyclin E-CDK2	Commits cell to DNA synthesis.
S phase	Cyclin A-CDK2	Supports DNA replication.
G2 to M	Cyclin B-CDK1	Also called maturation-promoting factor; initiates mitosis.

G₁/S Checkpoint: Rb, E2F, and p53

The G₁/S checkpoint determines whether a cell may replicate DNA. In its hypophosphorylated active state, retinoblastoma protein (Rb) binds and inhibits E2F, a transcription factor required for S-phase gene expression. Growth factor signaling increases cyclin D, activating CDK4/6, which phosphorylates Rb. Hyperphosphorylated Rb releases E2F, allowing transcription of DNA synthesis genes, including cyclin E.

p53, the “guardian of the genome,” responds to DNA damage, hypoxia, oncogene activation, and telomere shortening. DNA double-strand breaks activate ATM, whereas replication stress and single-strand DNA activate ATR. These kinases stabilize p53, which induces p21, a CDK inhibitor that blocks cyclin E-CDK2 and cyclin D-CDK4/6. This causes G₁ arrest, permitting DNA repair. If damage is irreparable, p53 promotes apoptosis through transcription of proapoptotic genes such as BAX, PUMA, and NOXA.

Clinically, loss of Rb or p53 removes critical brakes on proliferation. RB1 mutation is associated with retinoblastoma and osteosarcoma. TP53 mutation is the most common mutation in human cancer and is classically associated with Li-Fraumeni syndrome. DNA tumor viruses also target this checkpoint: HPV E7 inactivates Rb, while HPV E6 promotes p53 degradation via ubiquitination.

G₂/M and Spindle Checkpoints

The G₂/M checkpoint prevents mitosis if DNA replication is incomplete or DNA damage persists. Entry into mitosis requires activation of cyclin B-CDK1. CDK1 is inhibited by phosphorylation via Wee1 kinase and activated when Cdc25 phosphatase removes inhibitory phosphates. DNA damage activates checkpoint kinases, which inhibit Cdc25, delaying mitosis.

The spindle assembly checkpoint ensures that all chromosomes are properly attached to the mitotic spindle before anaphase. When kinetochores are correctly attached, the anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase, degrades securin. This releases separase, which cleaves cohesin rings holding sister chromatids together, allowing anaphase. APC/C also degrades cyclin B, promoting mitotic exit.

Cell Cycle Inhibitors and Cancer Pharmacology

Endogenous CDK inhibitors include the INK4 family, especially p16, which inhibits CDK4/6, and the CIP/KIP family, including p21 and p27. Loss of p16 function, amplification of cyclin D, or activating CDK4 mutations can drive unchecked G₁/S transition.

Drug/Class	Cell Cycle Target	High-Yield Mechanism
Vinca alkaloids	M phase	Inhibit microtubule polymerization; prevent spindle formation.
Taxanes	M phase	Stabilize microtubules; prevent depolymerization.
Antimetabolites	S phase	Inhibit DNA synthesis; examples include methotrexate, 5-fluorouracil, cytarabine.
Topoisomerase inhibitors	S/G2	Prevent DNA unwinding or religation, causing strand breaks.
CDK4/6 inhibitors	G1	Block Rb phosphorylation, maintaining E2F repression.

For Step 1, the key concept is that malignant transformation often reflects acquired ability to bypass checkpoints, resist apoptosis, maintain replicative potential, and proliferate independent of normal growth signals. Cell cycle regulation therefore links molecular biology directly to tumor suppressor genes, oncogenes, viral oncogenesis, and chemotherapy mechanisms.

Apoptosis, Necrosis and Autophagy

Apoptosis

Apoptosis is programmed, energy-dependent cell death designed to remove unwanted or irreparably injured cells without provoking inflammation. It is essential in embryogenesis, hormone-dependent tissue involution, deletion of autoreactive lymphocytes, and elimination of cells with DNA damage. Morphologically, apoptotic cells show cell shrinkage, chromatin condensation, nuclear fragmentation, membrane blebbing, and formation of apoptotic bodies that are rapidly phagocytosed. The plasma membrane remains intact, and phosphatidylserine is externalized as an “eat-me” signal.

The final common pathway is activation of caspases, cysteine proteases that cleave proteins after aspartate residues. Initiator caspases include caspase-8 and caspase-9; executioner caspases include caspase-3, -6, and -7. Caspase activation causes cytoskeletal breakdown, nuclear lamina cleavage, and DNA fragmentation into approximately 180–200 base-pair multiples, reflecting cleavage between nucleosomes.

Pathway	Trigger	Key molecules	High-yield associations
Intrinsic mitochondrial pathway	DNA damage, growth factor withdrawal, ER stress, misfolded proteins	BAX/BAK increase mitochondrial permeability; cytochrome c binds Apaf-1; apoptosome activates caspase-9	Regulated by BCL-2 family; p53 promotes apoptosis after severe DNA damage
Extrinsic death receptor pathway	Fas ligand or TNF binding to death receptors	Fas/CD95 recruits FADD; activates caspase-8	Important in cytotoxic T-cell killing and deletion of autoreactive lymphocytes

The BCL-2 family controls mitochondrial outer membrane permeability. Anti-apoptotic proteins include BCL-2 and BCL-XL; pro-apoptotic members include BAX, BAK, and BH3-only proteins such as BIM, BID, BAD, and PUMA. In follicular lymphoma, t(14;18) causes BCL-2 overexpression, preventing apoptosis and prolonging B-cell survival. In Step 1 pharmacology, several anticancer therapies work partly by inducing apoptosis through DNA damage or mitotic arrest; venetoclax, a BCL-2 inhibitor, is a mechanistically important example.

Laboratory detection includes TUNEL staining, which labels fragmented DNA, and annexin V staining, which detects externalized phosphatidylserine. In flow cytometry, annexin V-positive/propidium iodide-negative cells suggest early apoptosis, whereas annexin V-positive/propidium iodide-positive cells suggest late apoptosis or secondary necrosis.

Necrosis

Necrosis is uncontrolled cell death caused by severe injury, usually with ATP depletion, membrane damage, ion imbalance, cellular swelling, and enzymatic digestion. Unlike apoptosis, necrosis typically causes inflammation because disrupted membranes release intracellular contents and damage-associated molecular patterns such as ATP, uric acid, HMGB1, and mitochondrial DNA.

Early reversible injury includes cellular swelling due to failure of ATP-dependent Na⁺/K⁺-ATPase. Irreversible injury is marked by severe mitochondrial dysfunction, inability to restore oxidative phosphorylation, and loss of membrane integrity. In ischemic injury, ATP production falls rapidly within minutes; loss of calcium homeostasis activates phospholipases, proteases, endonucleases, and ATPases, worsening membrane and nuclear damage.

Pattern of necrosis	Mechanism/morphology	Classic examples
Coagulative	Protein denaturation preserves tissue architecture for days	Ischemic infarction of solid organs except brain; myocardial infarction shows coagulative necrosis, grossly apparent about 4–12 hours after infarction
Liquefactive	Enzymatic digestion dominates, producing liquid debris	Brain infarcts; abscesses due to neutrophilic enzymes
Caseous	Friable, “cheese-like” necrotic center with granulomatous inflammation	Tuberculosis; some fungal infections
Fat necrosis	Lipase-mediated fat breakdown; free fatty acids bind calcium, producing saponification	Acute pancreatitis; traumatic breast injury
Fibrinoid necrosis	Immune complex and fibrin deposition in vessel walls	Vasculitis; malignant hypertension; preeclampsia
Gangrenous necrosis	Clinical term, often coagulative necrosis of limb; superimposed infection causes liquefaction	Dry or wet gangrene of extremities

Nuclear changes in necrosis progress through pyknosis nuclear shrinkage, karyorrhexis fragmentation, and karyolysis dissolution. These terms are frequently tested because they distinguish necrotic structural breakdown from the orderly nuclear fragmentation of apoptosis.

Autophagy

Autophagy is a regulated lysosomal degradation pathway that allows cells to recycle damaged organelles and macromolecules, especially during nutrient deprivation. It is primarily a survival mechanism, although excessive or dysregulated autophagy may contribute to cell death. The best-tested form is macroautophagy, in which cytoplasmic contents are enclosed in a double-membrane autophagosome that fuses with a lysosome to form an autolysosome.

Autophagy is controlled by nutrient-sensing pathways. mTOR inhibits autophagy when nutrients and growth factors are abundant. During starvation, low ATP and increased AMP activate AMP-activated protein kinase, which inhibits mTOR and activates the ULK1 complex, initiating autophagosome formation. The Beclin-1 complex promotes nucleation, and LC3-I is lipidated to LC3-II, which associates with autophagosomal membranes. The adaptor protein p62/SQSTM1 binds ubiquitinated cargo and is degraded during autophagy; accumulation of p62 can indicate impaired autophagic flux.

• Physiologic roles: adaptation to fasting, organelle quality control, removal of protein aggregates, and defense against intracellular pathogens.
• Pathologic associations: neurodegenerative disease with protein aggregation, cancer cell survival under hypoxia or nutrient limitation, and liver injury with accumulation of damaged mitochondria.
• Pharmacologic correlation: mTOR inhibitors such as sirolimus promote autophagy conceptually by reducing mTOR signaling; chloroquine and hydroxychloroquine impair lysosomal acidification and can block late autophagic degradation.

For Step 1, the key distinction is functional: apoptosis is programmed noninflammatory cell deletion, necrosis is injurious inflammatory cell death with membrane rupture, and autophagy is lysosome-mediated cellular recycling that often helps a stressed cell survive.

Cellular Adaptation: Hypertrophy, Hyperplasia, Atrophy, Metaplasia and Dysplasia

Hypertrophy

Hypertrophy is an increase in individual cell size, producing an enlarged organ without an increased number of cells. It occurs especially in permanent cells with limited proliferative capacity, such as cardiac and skeletal muscle. The stimulus is usually increased functional demand or trophic signaling.

• Physiologic hypertrophy: skeletal muscle enlargement with exercise; uterine smooth muscle hypertrophy during pregnancy due to estrogen stimulation.
• Pathologic hypertrophy: left ventricular hypertrophy from chronic hypertension or aortic stenosis.

Mechanistically, mechanical stretch and growth factors activate signaling pathways such as PI3K-AKT-mTOR, MAPK, and Gq-mediated calcineurin-NFAT signaling. These increase protein synthesis, sarcomere assembly, and expression of “fetal” cardiac genes such as ANP, BNP, and β-myosin heavy chain. Initially adaptive, hypertrophy can become maladaptive when cellular oxygen demand exceeds vascular supply, predisposing to ischemia, arrhythmia, and heart failure.

Hyperplasia

Hyperplasia is an increase in cell number due to proliferation of mature cells and/or tissue stem cells. It requires cells capable of entering the cell cycle; therefore, it occurs in labile tissues such as skin, intestinal epithelium, and bone marrow, and in some stable tissues such as liver.

• Physiologic hormonal hyperplasia: breast glandular epithelium at puberty and pregnancy; endometrial proliferation during the menstrual cycle.
• Physiologic compensatory hyperplasia: liver regeneration after partial hepatectomy. Hepatocytes re-enter the cell cycle from G₀ under influence of HGF, TGF-α, IL-6, and TNF.
• Pathologic hyperplasia: endometrial hyperplasia from unopposed estrogen; benign prostatic hyperplasia driven by dihydrotestosterone; viral wart formation from HPV-induced epithelial proliferation.

Hyperplasia remains growth-factor dependent and is potentially reversible, unlike neoplasia. However, pathologic hyperplasia can create a fertile background for mutations; for example, atypical endometrial hyperplasia is a precursor to endometrioid carcinoma.

Atrophy

Atrophy is shrinkage of cell size, and sometimes cell number, resulting in a smaller organ. It reflects decreased protein synthesis and increased protein degradation. Major mechanisms include the ubiquitin-proteasome pathway, which degrades cytosolic proteins, and autophagy, in which organelles are enclosed in autophagic vacuoles and delivered to lysosomes.

Cause of Atrophy	Classic Example	Mechanism
Disuse	Limb immobilization in a cast	Reduced mechanical load lowers protein synthesis
Denervation	Skeletal muscle wasting after lower motor neuron injury	Loss of trophic neural stimulation
Ischemia	Renal cortical atrophy from renal artery stenosis	Reduced oxygen and nutrient delivery
Inadequate nutrition	Cachexia in cancer	TNF and inflammatory cytokines promote proteolysis
Loss of endocrine stimulation	Endometrial atrophy after menopause	Reduced hormone-dependent growth signaling
Aging	Brain atrophy in elderly patients	Accumulated cellular damage and reduced regenerative capacity

Autophagic residual bodies containing indigestible lipid-protein complexes form lipofuscin, a yellow-brown “wear-and-tear” pigment. In the heart, accumulation of lipofuscin with atrophy produces brown atrophy.

Metaplasia

Metaplasia is a reversible replacement of one differentiated adult cell type by another better suited to tolerate a chronic stress. It occurs through reprogramming of tissue stem cells, not direct conversion of one mature cell into another. Persistent injury, cytokines, growth factors, and extracellular matrix signals alter transcription factor expression and lineage commitment.

• Squamous metaplasia: respiratory pseudostratified ciliated columnar epithelium becomes stratified squamous epithelium in smokers. This improves resistance to smoke injury but impairs mucociliary clearance and predisposes to infection and squamous dysplasia.
• Columnar metaplasia: Barrett esophagus, in which distal esophageal stratified squamous epithelium is replaced by nonciliated columnar epithelium with goblet cells due to chronic gastroesophageal reflux. It increases risk of esophageal adenocarcinoma.
• Vitamin A deficiency: promotes squamous metaplasia because retinoic acid normally maintains mucous-secreting epithelial differentiation.
• Mesenchymal metaplasia: connective tissue may form cartilage, bone, or adipose tissue, as in myositis ossificans.

Dysplasia

Dysplasia means disordered cellular growth and maturation. It is not an adaptive response in the same benign sense as hypertrophy or atrophy; it is a premalignant epithelial change that may be reversible if the inciting stimulus is removed, but it can progress to carcinoma.

Microscopic features include pleomorphism, enlarged hyperchromatic nuclei, increased nuclear-to-cytoplasmic ratio, irregular nuclear contours, loss of polarity, architectural disorganization, and increased or abnormal mitoses. Dysplasia is confined above the basement membrane. Once neoplastic cells invade through the basement membrane into stroma, the lesion is no longer carcinoma in situ but invasive carcinoma.

Term	Key Finding	Clinical Significance
Mild dysplasia	Atypia limited to lower one-third of epithelium	Often reversible
Moderate dysplasia	Atypia extends into lower two-thirds	Higher progression risk
Severe dysplasia / carcinoma in situ	Full-thickness atypia with intact basement membrane	Preinvasive malignancy

A classic Step 1 example is cervical intraepithelial neoplasia: CIN 1 involves the lower one-third, CIN 2 the lower two-thirds, and CIN 3 more than two-thirds to full thickness. High-risk HPV types 16 and 18 cause approximately 70% of cervical cancers by expressing E6, which promotes p53 degradation, and E7, which inhibits Rb, releasing E2F and driving inappropriate G₁ to S-phase progression.